Hidden Opportunities for Healthcare Professionals with Workshop on Book Writing & Publishing

02/Apr/2015

PLA is pleased to announce the Webinar on “Hidden Opportunities for Healthcare Professionals with Workshop on Book Writing & Publishing” by the World renowned Author and Trainer, Dr. Krishna N. Sharma. This webinar along with a Workshop would be a great opportunity to explore the Hidden additional Opportunities that you can do parallel to your mainstream profession, and BE AN AUTHOR.

For details and registration visit: http://www.myespace.co.in

 

 

Or Contact at:
Email: info@physislearningacademy.com

 

Whats App: +91 9873470126


Ph: +91 999 980 2018

 

 

Pharmacovigilance, Drug Safety and Risk Management: Hear an Exclusive keynote Address from PRAC

13/Mar/2015

In recent weeks, the European Medicines Agency (EMA) published a report to support the implementation of a new international standard for the safety monitoring of medicines in the European Union (EU). The new standard (ISO ICSR) improves the reporting of suspected side effects of medicines in Individual Case Safety Reports (ICSRs) and will take effect from 1 July 2016.*

Hear more from the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), who will be delivering an exclusive keynote address at SMi’s 4th annual Pharmacovigilance, Drug Safety & Risk Management conference when it returns to London on the 11th – 12th May 2015.

The address presented by PRAC member Doris Irene Stenver, Chief Medical Officer from the Danish Health & Medicines Agency, will provide the latest PRAC updates and discuss optimising the outcome of risk assessments and risk minimisation measures. Other key features of her presentation will include insights into the Integration of stakeholders and signal management processes in the EU.

Confirmed attendees include: Bluefish pharmaceuticals, Daiichi Sankyo UK Ltd, Danish Medicines Agency, Drug Safety Research Unit, EudraVigilance Consultants, MedDRA Maintenance and Support Services Organisation (MSSO), NDA Regulatory Science Ltd, Novartis International AG, Novonordisk, Pfizer Ltd, pharsafer associates, Quintiles, Roche Products Limited, Royal College of Physicians London, Solvay Pharmaceuticals, Takeda Chemical Industries Ltd, TEVA Pharmaceuticals, Vifor Pharma

For more information or to download a brochure visit:

http://www.smi-online.co.uk/goto/2015pharmacovigilance44.asp

Pharmacovigilance, Drug Safety and Risk Management
11th – 12th May 2015
Holiday Inn Regents Park Hotel, London, UK.
http://www.smi-online.co.uk/goto/2015pharmacovigilance44.asp

About SMI Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

*Source: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_and_events.jsp

Pharmacovigilance, Drug Safety and Risk Management: Hear an Exclusive keynote Address from PRAC

13/Mar/2015

In recent weeks, the European Medicines Agency (EMA) published a report to support the implementation of a new international standard for the safety monitoring of medicines in the European Union (EU). The new standard (ISO ICSR) improves the reporting of suspected side effects of medicines in Individual Case Safety Reports (ICSRs) and will take effect from 1 July 2016.*

Hear more from the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), who will be delivering an exclusive keynote address at SMi’s 4th annual Pharmacovigilance, Drug Safety & Risk Management conference when it returns to London on the 11th – 12th May 2015.

The address presented by PRAC member Doris Irene Stenver, Chief Medical Officer from the Danish Health & Medicines Agency, will provide the latest PRAC updates and discuss optimising the outcome of risk assessments and risk minimisation measures. Other key features of her presentation will include insights into the Integration of stakeholders and signal management processes in the EU.

Confirmed attendees include: Bluefish pharmaceuticals, Daiichi Sankyo UK Ltd, Danish Medicines Agency, Drug Safety Research Unit, EudraVigilance Consultants, MedDRA Maintenance and Support Services Organisation (MSSO), NDA Regulatory Science Ltd, Novartis International AG, Novonordisk, Pfizer Ltd, pharsafer associates, Quintiles, Roche Products Limited, Royal College of Physicians London, Solvay Pharmaceuticals, Takeda Chemical Industries Ltd, TEVA Pharmaceuticals, Vifor Pharma

For more information or to download a brochure visit:

http://www.smi-online.co.uk/goto/2015pharmacovigilance44.asp

Pharmacovigilance, Drug Safety and Risk Management
11th – 12th May 2015
Holiday Inn Regents Park Hotel, London, UK.
http://www.smi-online.co.uk/goto/2015pharmacovigilance44.asp

About SMI Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

*Source: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_and_events.jsp

Physis Journey So Far

01/Oct/2014

Physis Learning Academy Pvt. Ltd. thanks our associates and healthcare fraternity for their continuous support and assistance in establishing our presence globally & shaping up our goals. We are pleased to share the footsteps of our journey so far with you all. To further excel the healthcare community and to serve us in a better way, we invite your feedbacks and comments at info@physislearningacademy.com

NEWSLETTER: PLA JOURNEY SO FAR..

CDSCO New Order Dated 5 Sep 2014

17/Sep/2014

CDSCO new order dated 05 Sep 2014; New clinical trial should be evaluated regarding three parameter
a). assessment of risk versus benefit to the patients
b). innovation vis-à-vis existing therapeutic option
c). unmet medical need in country
 
Please visit the link for complete details
1 of 4Next